He comes to the San Diego-based firm from protein therapeutics firm Xencor of Monrovia, Calif., where he was president and CEO, and where he will remain a director. Sequenom has been without a full-time chief since February, when Toni Schuh resigned. Stylli takes over from Steve Zaniboni, who led Sequenom on an interim basis.
Prior to Xencor, he was president, CEO, and a co-founder of therapeutic antibody maker CovX Pharmaceuticals.
Stylli also co-founded Aurora Biosciences in 1995, where he was senior vice president of screening technology and new ventures, and later senior vice president of commercial development. In 2001, when
As part of his employment package at Sequenom, Stylli received stock options for 1 million shares of common stock.
Stylli holds a PhD from